FibroBiologics reports Q3 EPS (13c), two estimates (12c)

“This quarter brought our strategy into greater focus,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics (FBLG). “We are efficiently moving our most advanced product candidates towards the clinic while laying the groundwork to demonstrate that fibroblasts can be a scalable platform and not simply a single-asset bet. Our fibroblast platform will enter the clinic with our Phase 1/2 trial in diabetic foot ulcer patients in the first quarter next year, as we execute against defined milestones to validate its biology, the technology, and the regulatory and commercial path forward.”